(Boursier.com) — Abivax SA, a clinical-stage biotechnology company focused on the development of therapeutic treatments that exploit the body’s natural regulatory mechanisms to modulate the immune response in patients suffering from chronic inflammatory diseases, today announces the presentation of three abstracts scientists regarding its lead drug candidate, obefazimod, at the United European Gastroenterology (UEG) Week conference, October 14-17, 2023, in Copenhagen, Denmark.
“We continue to be encouraged by the clinical profile of obefazimod emerging based on the efficacy and safety data generated at 96 weeks of treatment in our open-label Phase 2b maintenance study,” said Sheldon Sloan, MD, M. Bioethics, Medical Director of Abivax. “With the presentation of this new data and the novel underlying mechanism of action, obefazimod has the potential to shift the treatment paradigm to benefit people with ulcerative colitis.”
©2023 Boursier.com